Literature DB >> 19653337

Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonine.

Sakineh Kazemi Noureini1, Michael Wink.   

Abstract

AIM: To investigate the potential effects of chelidonine, the main alkaloid of Chelidonium majus, on telomerase activity and its regulation in HepG2 cells.
METHODS: Cytotoxicity of chelidonine for HepG2 cells was determined by neutral red assay. A modified polymerase chain reaction (PCR)-based telomerase repeat amplification protocol was used to estimate relative telomerase activity in chelidonine-treated cells in comparison with the untreated control cells. Relative expression level of the catalytic subunit of telomerase (hTERT) gene and P-glycoprotein (pgp) were estimated using semi-quantitative real-time reverse transcription-PCR (RT-PCR). Cell senescence in treated cells was demonstrated using a beta-galactosidase test.
RESULTS: Cytotoxicity of chelidonine in HepG2 cells was not dose-dependent and tended to reach plateau immediately after the living cells were reduced in number to slightly higher than 50%. However, 12 micromol/L concentration of chelidonine was considered as LD(50), where the maximal attainable effects were realized. Real-time RT-PCR data showed that the expression of pgp increased three-fold in chelidonine treated HepG2 cells in comparison with the untreated controls. Morphologically, treated HepG2 cells showed apoptotic features after 24 h and a small fraction of cells appeared with single blister cell death. The relative expression level of Bcl-2 dropped to less than 50% of control cells at a sub-apoptotic concentration of chelidonine and subsequently increased to higher than 120% at LD(50). Telomerase activity was reduced considerably after administration of very low doses of chelidonine, whereas higher concentrations of chelidonine did not remarkably enhance the effect. Real-time RT-PCR experiments indicated a drastic decrease in expression level of hTERT subunit of telomerase under treatment with chelidonine. Repeated treatment of cells with very low doses of chelidonine caused a decline in growth rate by 4 wk and many of the cells appeared to be aged with large volume and dark staining in the beta-galactosidase assay.
CONCLUSION: Chelidonine reduces telomerase activity through down-regulation of hTERT expression. Senescence induction might not be directly caused by reducing telomerase activity as it occurs after a few population doublings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19653337      PMCID: PMC2721233          DOI: 10.3748/wjg.15.3603

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase.

Authors:  A Ludwig; G Saretzki; P S Holm; F Tiemann; M Lorenz; T Emrich; C B Harley; T von Zglinicki
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

2.  The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro.

Authors:  A Panzer; A M Joubert; P C Bianchi; J C Seegers
Journal:  Cancer Lett       Date:  2000-03-13       Impact factor: 8.679

Review 3.  Switching and signaling at the telomere.

Authors:  E H Blackburn
Journal:  Cell       Date:  2001-09-21       Impact factor: 41.582

Review 4.  Ukrain: a novel antitumor drug.

Authors:  K N Uglyanitsa; L I Nefyodov; Y M Doroshenko; J W Nowicky; I V Volchek; W J Brzosko; Y J Hodysh
Journal:  Drugs Exp Clin Res       Date:  2000

5.  A highly selective telomerase inhibitor limiting human cancer cell proliferation.

Authors:  K Damm; U Hemmann; P Garin-Chesa; N Hauel; I Kauffmann; H Priepke; C Niestroj; C Daiber; B Enenkel; B Guilliard; I Lauritsch; E Müller; E Pascolo; G Sauter; M Pantic; U M Martens; C Wenz; J Lingner; N Kraut; W J Rettig; A Schnapp
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

6.  The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways.

Authors:  A Panzer; A M Joubert; P C Bianchi; E Hamel; J C Seegers
Journal:  Eur J Cell Biol       Date:  2001-01       Impact factor: 4.492

7.  Telomerase modulates expression of growth-controlling genes and enhances cell proliferation.

Authors:  Laura L Smith; Hilary A Coller; James M Roberts
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

Review 8.  Telomerase and human tumorigenesis.

Authors:  S A Stewart; R A Weinberg
Journal:  Semin Cancer Biol       Date:  2000-12       Impact factor: 15.707

9.  Efficacy of a plant extract (Chelidonium majus L.) in combating induced hepatocarcinogenesis in mice.

Authors:  S J Biswas; N Bhattacharjee; A R Khuda-Bukhsh
Journal:  Food Chem Toxicol       Date:  2007-12-15       Impact factor: 6.023

Review 10.  Telomerase: a target for cancer therapeutics.

Authors:  Jerry W Shay; Woodring E Wright
Journal:  Cancer Cell       Date:  2002-10       Impact factor: 31.743

View more
  9 in total

1.  Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.

Authors:  Hei Cheul Jeung; Sun Young Rha; Sang Joon Shin; Joong Bae Ahn; Kyu Hyun Park; Tae Soo Kim; Jin Ju Kim; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

2.  A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.

Authors:  Koppany Visnyei; Hideyuki Onodera; Robert Damoiseaux; Kuniyasu Saigusa; Syuzanna Petrosyan; David De Vries; Denise Ferrari; Jonathan Saxe; Eduard H Panosyan; Michael Masterman-Smith; Jack Mottahedeh; Kenneth A Bradley; Jing Huang; Chiara Sabatti; Ichiro Nakano; Harley I Kornblum
Journal:  Mol Cancer Ther       Date:  2011-08-22       Impact factor: 6.261

3.  Pro-apoptotic effects of tectorigenin on human hepatocellular carcinoma HepG2 cells.

Authors:  Chun-Ping Jiang; Hui Ding; Da-Hua Shi; Yu-Rong Wang; Er-Guang Li; Jun-Hua Wu
Journal:  World J Gastroenterol       Date:  2012-04-21       Impact factor: 5.742

Review 4.  Modes of Action of Herbal Medicines and Plant Secondary Metabolites.

Authors:  Michael Wink
Journal:  Medicines (Basel)       Date:  2015-09-08

5.  UPLC-MS/MS Profile of Alkaloids with Cytotoxic Properties of Selected Medicinal Plants of the Berberidaceae and Papaveraceae Families.

Authors:  Anna Och; Katarzyna Szewczyk; Łukasz Pecio; Anna Stochmal; Daniel Załuski; Anna Bogucka-Kocka
Journal:  Oxid Med Cell Longev       Date:  2017-08-30       Impact factor: 6.543

6.  Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells.

Authors:  Fang-Jie Hou; Li-Xiao Guo; Kai-Yan Zheng; Jun-Na Song; Qian Wang; Yu-Guang Zheng
Journal:  Onco Targets Ther       Date:  2019-08-19       Impact factor: 4.147

7.  The β-carboline alkaloid harmine inhibits telomerase activity of MCF-7 cells by down-regulating hTERT mRNA expression accompanied by an accelerated senescent phenotype.

Authors:  Lei Zhao; Michael Wink
Journal:  PeerJ       Date:  2013-10-01       Impact factor: 2.984

Review 8.  Greater Celandine's Ups and Downs-21 Centuries of Medicinal Uses of Chelidonium majus From the Viewpoint of Today's Pharmacology.

Authors:  Sylwia Zielińska; Anna Jezierska-Domaradzka; Magdalena Wójciak-Kosior; Ireneusz Sowa; Adam Junka; Adam M Matkowski
Journal:  Front Pharmacol       Date:  2018-04-11       Impact factor: 5.810

9.  Telomere shortening in breast cancer cells (MCF7) under treatment with low doses of the benzylisoquinoline alkaloid chelidonine.

Authors:  Sakineh Kazemi Noureini; Leili Fatemi; Michael Wink
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.